Parkinson's disease

• 1. The Shaking Palsy

  ›

  In 1817, English physician James Parkinson published a monograph titled An Essay on the Shaking Palsy. He described six clinical cases he had observed walking near Hoxton Square in London. The essay detailed three cardinal symptoms: tremor, postural instability, and paralysis. Parkinson speculated that trauma to the spinal cord caused this condition. No one else investigated the shaking palsy for over forty years until Jean-Martin Charcot began expanding the description in 1861. Charcot added bradykinesia as a fourth symptom and renamed the disease after Parkinson in 1877.

• 2. Dopamine And Lewy Bodies

  ›

  Parkinson's disease involves the gradual decay of dopamine-producing neurons in the substantia nigra region of the brain. This loss is accompanied by the accumulation of misfolded proteins called alpha-synuclein. These proteins build up to form clumps known as Lewy bodies if not cleared from cells. Microglia release pro-inflammatory molecules when these clumps accumulate. Chronic inflammation can cause neuronal damage and disrupt metabolic systems. By the time motor symptoms appear, fifty to eighty percent of all dopaminergic neurons have already degenerated.

  4

• 3. Genes And Toxins

  ›

  About five to ten percent of cases are familial while others remain idiopathic with no clearly identifiable cause. Variations in specific genes like SNCA and LRRK2 act as risk factors. Environmental exposures to pesticides such as paraquat and glyphosate are increasingly seen as major contributors. Air pollution and trichloroethylene also link to PD development. The brain is particularly vulnerable to chemicals that cross the blood-brain barrier. Traumatic brain injury significantly increases PD risk alongside Type 2 diabetes.

  56

• 4. Clinical Diagnosis Challenges

  ›

  Diagnosis relies primarily on signs and symptoms identified through neurological examination. Medical imaging techniques like PET scanning support the diagnosis but cannot confirm it alone. A typical diagnosis requires responsiveness to levodopa or resting tremor. Misdiagnosis occurs at a rate near twenty-five percent during follow-ups. Atypical parkinsonian disorders including multiple system atrophy often mimic early Parkinson's disease. Definitive diagnoses can only be made post mortem through pathological analysis.

  2

• 5. Medications And Surgery

  ›

  Levodopa remains the most widely used and effective therapy for treating motor symptoms. Its administration has been called the pharmacologist's nightmare due to side effects like nausea and vomiting. Long-term use may induce dyskinesia and motor fluctuations. Deep brain stimulation emerged in the late 1980s as an alternative when medications fail. This procedure involves implanting electrodes into specific parts of the brain. It targets rigidity and tremor but does not slow disease progression.

  6

• 6. A Century Of Discovery

  ›

  Frederic Lewy described microscopic particles in affected brains in 1912, later named Lewy bodies. Konstantin Tretiakoff reported that the substantia nigra was the main structure affected in 1919. Arvid Carlsson and Oleh Hornykiewicz identified underlying changes in dopamine signaling during the 1950s. Polymeropoulos discovered the first gene for PD, SNCA, in 1997. Levodopa did not enter clinical use until 1967 despite being synthesized by Casimir Funk in 1911. Alim Louis Benabid introduced deep brain stimulation at Grenoble, France, by the late 1980s.

  3

• 7. The Economic Burden

  ›

  In 2010, the total economic burden of Parkinson's across Europe reached €13.9 billion. The United States estimated a cost of $51.9 billion in 2017, projected to surpass $79 billion by 2037. Family members dedicate around twenty-two hours per week to care for patients. Public health systems in low- and middle-income countries often fail to cover therapies fully. The number of cases is predicted to rise to over twelve million by 2040 due to increased life expectancy and industrialization.